Shilpee Sharma

Shilpee Sharma

Auto-generated profile, based on publicly available information

Shilpee Sharma

European Plotkin Institute for Vaccinology, Université libre de Bruxelles

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Cell Reports
Verified
Journal Article
Open access
MVMaria Vono
Maria Vono
AHAngela Huttner
Angela Huttner
SLSylvain Lemeille
Sylvain Lemeille
PMPaola Martinez-Murillo
Paola Martinez-Murillo
BMBenjamin Meyer
Benjamin Meyer
ADArnaud M. Didierlaurent
Arnaud M. Didierlaurent
SARS-CoV-2 infection in children is less severe than it is in adults. We perform a longitudinal analysis of the early innate responses in children and adults with mild infection within household clusters. Children display fewer symptoms than adults do, despite similar initial viral load, and mount a robust anti-viral immune signature typical of the SARS-CoV-2 infection and characterized by early interferon gene responses; increases in cytokines, such as CXCL10 and GM-CSF; and changes in blood cell numbers. When compared with adults, the antiviral response resolves faster (within a week of symptoms), monocytes and dendritic cells are more transiently activated, and genes associated with B cell activation appear earlier in children. Nonetheless, these differences do not have major effects on the quality of SARS-CoV-2-specific antibody responses. Our findings reveal that better early control of inflammation as observed in children may be key for rapidly controlling infection and limiting the disease course.

1 December 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MBMahesh Bachu
Mahesh Bachu
SYSwarupa Yalla
Swarupa Yalla
MAMangaiarkarasi Asokan
Mangaiarkarasi Asokan
AVAnjali Verma
Anjali Verma
Ujjwal NeogiUjjwal Neogi
Ujjwal Neogi
URUday Kumar Ranga
Uday Kumar Ranga
We demonstrate that at least three different promoter variant strains of HIV-1 subtype C have been gradually expanding and replacing the standard subtype C viruses in India, and possibly in South Africa and other global regions, over the past decade. The new viral strains contain an additional NF-κB, NF-κB-like, or RBEIII site in the viral promoter. Although the acquisition of an additional RBEIII site is a property shared by all the HIV-1 subtypes, acquiring an additional NF-κB site remains an exclusive property of subtype C. The acquired κB site is genetically distinct, binds the p50-p65 heterodimer, and strengthens the viral promoter at the levels of transcription initiation and elongation. The 4-κB viruses dominate the 3-κB “isogenic” viral strains in pairwise competition assays in T-cell lines, primary cells, and the ecotropic human immunodeficiency virus mouse model. The dominance of the 4-κB viral strains is also evident in the natural context when the subjects are coinfected with κB-variant viral strains. The mean plasma viral loads, but not CD4 counts, are significantly different in 4-κB infection suggesting that these newly emerging strains are probably more infectious. It is possible that higher plasma viral loads underlie selective transmission of the 4-κB viral strains. Several publications previously reported duplication or deletion of diverse transcription factor-binding sites in the viral promoter. Unlike previous reports, our study provides experimental evidence that the new viral strains gained a potential selective advantage as a consequence of the acquired transcription factor-binding sites and importantly that these strains have been expanding at the population level.

1 January 2014 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
LRLakshmi Narashimhan Ramana
Lakshmi Narashimhan Ramana
SSShilpee Sharma
Shilpee Sharma
SSSwaminathan Sethuraman
Swaminathan Sethuraman
URUdaykumar Ranga
Udaykumar Ranga
UKUma Maheswari Krishnan
Uma Maheswari Krishnan

1 July 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LRLakshmi Narashimhan Ramana
Lakshmi Narashimhan Ramana
SSShilpee Sharma
Shilpee Sharma
SSSwaminathan Sethuraman
Swaminathan Sethuraman
URUdaykumar Ranga
Udaykumar Ranga
UKUma Maheswari Krishnan
Uma Maheswari Krishnan

1 January 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
LRLakshmi Narashimhan Ramana
Lakshmi Narashimhan Ramana
SSShilpee Sharma
Shilpee Sharma
SSSwaminathan Sethuraman
Swaminathan Sethuraman
URUdaykumar Ranga
Udaykumar Ranga
UKUma Maheswari Krishnan
Uma Maheswari Krishnan

24 January 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSShilpee Sharma
Shilpee Sharma
SAShambhu G. Aralaguppe
Shambhu G. Aralaguppe
MAMelissa-Rose Abrahams
Melissa-Rose Abrahams
CWCarolyn Williamson
Carolyn Williamson
CGClive Gray
Clive Gray
URUday Kumar Ranga
Uday Kumar Ranga
HIV-1 subtype C demonstrates several biological properties distinct from other viral subtypes. One such variation is the duplication of PTAP motif in p6 Gag. PTAP motif is a key player in viral budding. Here, we studied the prevalence of PTAP motif duplication in subtype C viral strains in a longitudinal study. In a prospective follow-up study, 65 HIV-1 seropositive drug-naive subjects were monitored in two different clinical cohorts of India for 2 years with repeated sampling at 6-month intervals. The viral RNA was extracted from plasma, the gag segment was amplified and sequenced. From a subset of viral isolates the sequences of pol, env and LTR were sequenced. Using HIV-1 gag amino acid sequences available from public databases and additional sequences derived from the Indian and South-African cohorts, we examined the nature of PTAP motif duplication in subtype C. In 16% (8 of 50) of the primary viral strains of India, we identified a sequence duplication of the PTAP motif in Gag p6. The length of the sequence duplication varied from 6 to 14 amino acids in the viral isolates but remained fixed within a subject over a period of 24–36 month follow-up. In the duplicated motif, the core PTAP motif was invariable, but the flanking residues were highly variable. In an acute phase clinical cohort of South Africa, in a subset of 75 subjects, we found the presence of the PTAP duplication at a frequency of 29.3%. An analysis of the gag sequences from the extant databases showed that unlike other subtypes of HIV-1, subtype C has a natural propensity to generate the PTAP motif duplication at a significantly higher frequency and of greater length. Additionally, the global prevalence of PTAP duplication in subtype C appears to be increasing progressively over the past 30 years. We showed that in subtype C, the duplication of the PTAP motif in p6 Gag involves sequence stretches of greater length, and at a much higher frequency as compared to other HIV-1 subtypes. Given that subtype C naturally lacks the Alix binding motif, the acquisition of an additional PTAP motif may confer replication advantage on this HIV-1 subtype. Further investigation is warranted to examine the significance of PTAP motif duplication on the replicative fitness of HIV-1.